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Abstract
Background
In December 2019, the World Health Organization (WHO) was informed of an outbreak of an
unknown cause of pneumonia-like symptoms in residents concentrated in Wuhan, China; this
marked the start of China’s epidemic, which transformed into a pandemic affecting all continents
of the world. The cause of the pneumonia-like symptoms was found to be due to the growth and
development of the virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which
spreads through an infected person’s respiratory droplets through activities such as talking,
coughing, and sneezing. With COVID-19 vaccine manufacturers available worldwide, even the
economically and technologically forward countries such as Thailand and China contain pockets
of residents without access to the COVID-19 vaccine to this day.
Objective
This paper will examine the potential use of herbal and medicinal plants as a form of treatment in
mitigating mild to moderate COVID-19 symptoms in diagnosed COVID-19 positive residents in
Thailand and China.
Methods
A comprehensive literature review was performed using PubMed and references cited in
UpToDate. Seven articles that focused on the topic were chosen for a narrative review. Based
upon the research literature, a proposal for further mixed-method study is presented.
Keywords: Epidemic, pandemic, COVID-19, SARS-CoV-2, China, Thailand,
complementary and alternative medicine, mild to moderate symptoms
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Introduction
In December 2019, the World Health Organization (WHO) was informed of an outbreak
of an unknown cause of pneumonia-like symptoms in Wuhan, China residents; this marked the
start of China’s epidemic, which in the blink of an eye transformed into a pandemic affecting all
continents of the world (McIntosh et al., 2021). The cause of the pneumonia-like symptoms was
due to the severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2) which spreads
through an infected person’s respiratory droplets through activities such as talking, coughing,
and sneezing. With these droplets being viable for up to a few days, the WHO emphasized the
importance of maintaining a physical distance of at least six feet, wearing a facial covering over
the nose and mouth, and strict hand hygiene as crucial steps in preventing the spread of
coronavirus disease of 2019 (COVID-19).
Although a handful of vaccine manufacturers worldwide have surpassed the research and
development phase and produced their formulated vaccine to combat the rapid spread of
COVID-19, even the economically and technologically forward countries such as Thailand and
China to this day contain pockets of residents without access to the COVID-19 vaccine.
Therefore, the purpose of this literature review and proposal for further study is to explore the
potential for Chinese and Thai herbal therapies to manage mild to moderate COVID-19
symptoms.
The research question is:
What is the efficacy of native Thai and Chinese herbal and medicinal plants as a
nonpharmacological intervention in mitigating mild-to-moderate COVID-19 symptoms for
patients in China compared to Thailand?
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Literature Review
In this narrative literature review, seven articles were obtained from databases such as
PubMed and UpToDate. The objective of this process is to identify articles demonstrating the
efficacy of herbal and medicinal plants native to China and Thailand in mitigating mild to
moderate COVID-19 symptoms. The articles found were narrowed by the year of publication,
type of research the literature was categorized as, and region the literature is concentrating on.
The acceptable time range of published studies needed to fall within December 2019 (start of the
COVID-19 widespread) until the current day (November 2021). The last search strategy used
pertains to the studied region, which for this particular literature review is focused on Thailand
and China.
The search terms used included terms such as herbal plants, medicinal plants, COVID-19,
traditional Eastern medicine, Thailand, China, SARS-CoV-2, antiviral, treatment, prevention,
herbal, traditional Chinese medicine, ethnobotany, mild COVID-19 symptoms, mild to moderate
COVID-19 symptoms, moderate COVID-19 symptoms, meta-analysis, systematic review,
coronavirus, and anti- SARS-CoV-2. An example of a search entry used on PubMed was
COVID-19 [OR] SARS-CoV-2 [AND] China [OR] Thailand [AND] herbal plants [OR]
medicinal plants [AND] treatment.
In the process of sifting through the databases available through Dominican University of
California’s library webpage, PubMed, UpToDate, Cochrane Library, and the US National
Library of Medicine National Institute of Health (PMC) yielded the most relevant information
regarding the proposed topic. Seven articles selected by the mentioned criteria were chosen to
support the research questions posed regarding the efficacy of herbal and medicinal plants native
to China and Thailand in relieving mild to moderate COVID-19 symptoms are organized into
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three categories: herbal and medicinal plants used to mitigate mild to moderate COVID-19
symptoms in Thailand, China, and studies of adaptations made to traditional Chinese medicine
used for COVID-19 patients.
The Use of Herbal and Medicinal Plants Native to Thailand for Mitigating Mild to
Moderate COVID-19 Symptoms
From January 3, 2020, to October 18, 2021, COVID-19 cases in Thailand ranks 24 of
223, and 69.8 million people in 2020, there were 1,793,812 reported positive COVID-19 cases,
1,668,250 recoveries, 18,336 deaths, and 10,111 daily new cases (Thailand: Who coronavirus
disease (covid-19) dashboard with vaccination data, n.d.). In terms of COVID-19 vaccination
status, although 59,258,667 vaccine doses have been administered, 35,462,170 people have been
vaccinated with at least one dose and 23,796,497 are considered as fully vaccinated (dependent
on the vaccine manufacturer). Three articles were chosen to demonstrate the use of herbal and
medicinal plants in Thailand by identifying which species of plants contain anti-SARS-CoV-2
mechanisms, which parts of the plant have the highest antiviral effect, and uses among Thai
Karen and Hmong residents.
The article titled, “High-content screening of Thai medicinal plants reveals Boesenbergia
rotunda extract and its component Panduratin A as anti-SARS-CoV-2 agents” details the
extensive work to develop a high-content screening method for potential antiviral plants
(Kanjanasirirat et al., 2020). The researchers used SARS-CoV-2 nucleoprotein detection to
measure the amount of plaque reduction assay and dose-response analysis to indicate the
effectiveness of the identified herbal and medicinal plants in viral suppression. With a sample
size of 122 Thai medicinal plants, the researchers developed a quantitative experimental research
design using a two-step approach: pre-entry and post-infectious treatments. The pre-entry
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approach of the quantitative experiment was described as pre-incubating each of the Thai herbal
plants’ natural extracts with the SARS-CoV-2 virus strain into a test tube before being
inoculated. The post-infectious portion of their experiment was carried out by introducing the
natural extracts to the cell culture after viral infection in which the effectiveness of the viral
suppression activity was observed for the duration of the experiment.
Of the three plant extracts experimented on, Panduratin A (extract named B. rotunda)
demonstrated the highest inhibitory concentration against the SARS-CoV-2 virus during both the
pre-entry and post-infection phase as well as successfully suppressing viral growth when
exposed to extracted human’s airway epithelial cells in a controlled manner. Three main
strengths were identified: the results from their study were thoroughly performed and collected
as they measure the outcome of the chosen medicinal plants through both dose-response
relationship and plaque assay reduction, a large study sample of one hundred twenty-two
potential native Thai medicinal plants to be tested were studied in detail in preparation for their
experiment, and beyond testing the impact of the B. rotunda extract from the Panduratin A plant
on the post-infection phase, the researchers expanded their study and tested whether the two
components would have an effect for pre-entry treatment which also showed successful results.
One major limitation the authors stated about their product was, “it has prompted us to develop,
for the first time, a high-content screening platform” which indicates a possible lack of
credibility with the results found as their same study has not been able to be replicated by others
in a way to obtain the same experimental results (Kanjanasirirat et al., 2020, pg. 2).
The next article to be included in this comprehensive literature review is “Rapid selection
of Andrographis paniculata medicinal plant materials based on major bioactive using nearinfrared spectroscopy” which is a quantitative study focusing on developing experimental
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research that determines the efficacy of the Andrographis paniculata Thai medicinal plant on its
antiviral activity against SARS-CoV-2. For this study, one hundred and seventy samples
(collected from ten provinces of Thailand including Bangkok, Nakhon Pathom, Nonthaburi,
Prajeenburi, Phetchaburi, Phetchabun, Mahasarakham, Suphanburi, and Sa Kaeo) of the plant
were obtained over two years which were categorized into four groups: aerial, stems, leaves, and
stems mixed with leaves (Kasemsumran et al., 2021). Fresh samples of the Andrographis
paniculata plant were made into a powder form being dried at 50 degrees Celsius for ten hours
and then mechanically ground, then placed into their respective test tube for near-infrared
spectrophotometer (NIR) testing.
The NIR technique was chosen by the researchers as the plants did not have to be
extracted prior and had the lowest risk of destroying or tampering with the sample in the process.
Additionally, because of the difficulty in distinguishing the parts of the plant after thorough
grinding, this was another reason which prompted the researchers to create an experiment to
quantify the contents with the NIR banding method. The Partial Least Squares-Discriminant
Analysis method (PLS-DA) showed success in classifying the results in the controlled and
experimental test tubes. From the different plant parts included in the experiment, the leaves only
test tubes were found to yield the highest content of bioactive compounds as well as
andrographolide (AP1) whereas in the test tubes which contained a mixture of the Andrographis
paniculate leaves and arterial parts contained the highest amount of dehydroandrographolide
(AP3). AP1 is a chemical compound that interferes with the reproduction of malignant cells such
as those replicated by the SARS-CoV-2 virus, while AP3 is found to be an anti-inflammatory
and antiviral agent.
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The last article which magnifies the use of native Thai herbal and medicinal plants in
mitigating mild COVID-19 symptoms is “Medicinal Plants Used for Treating Mild Covid-19
Symptoms Among Thai Karen and Hmong”. This study includes a compiled literature review
and qualitative study executed in the form of field interviews with a total of 1,230 use reports of
medicinal plants among residents in the Thai Karen (555 reports) and Hmong (675 reports)
communities with mild COVID-19 symptoms (Phumthum et al., 2021). Additionally, sixteen
local healers were included in this study as they primarily use medicinal herbs and ethnobotany
practices to treat the symptoms experienced. Four hundred ninety-one plant species were
identified among the Thai Karen and Hmong communities to alleviate symptoms of fever
(commonly Acorus calamus, Strobilanthes cusia, and Melicope glomerata), cough (commonly
Zingiber officinale, Blumea balsamifera, and Elephantopus scaber), and diarrhea (Psidium
guajava and Zingiber ottensii) labeled as mild COVID-19 symptoms by the World Health
Organization (WHO).
With the rapid spread of COVID-19 worldwide, identification of these plants native to
Thailand provides significant information which could alleviate the strain on healthcare workers,
institutions, as well as benefit residents in Thailand who may be isolated due to living situations
or access to healthcare and the COVID-19 vaccine.
Using Traditional Chinese Medicine Alongside Western Medicine

Examining the Use of Integrative Medicine: Using Traditional Chinese Medicine Alongside
Western Medicine
From January 3, 2020, to October 18, 2021, China ranks 133 of 223 as there have been a
total of 125,254 confirmed cases, 5,695 deaths, and a total of 2,228,305,003 vaccine doses
administered (1,014,573,856 people being fully vaccinated) (China: Who coronavirus disease
(covid-19) dashboard with vaccination data, n.d.). To examine the use of integrative medicine
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using traditional Chinese medicine (TCM) alongside conventional Western medicine (CWM),
two primary articles demonstrate the benefits of using both practices concurrently for better
outcomes in patients diagnosed with COVID-19.
“Chinese herbal medicine for coronavirus disease 2019: A systematic review and metaanalysis” summarizes the results of eighteen randomized controlled trials on 2,275 COVID-19
positive patients using traditional Chinese herbal medicine in mainland China (Xiong et al.,
2020). Two groups were studied: the control group receiving conventional Western medicine
and/or a combination of Chinese herbal medicine placebo while the treatment (experimental)
group was treated by Chinese herbal medicine and/or alongside conventional Western medicine.
To ensure continuity in the interventions between the two groups, the medication used for the
Western medicine practice was given by the same dosage, route of administration, and usage.
The experimental results were primarily monitored in the form of multiple lung CT scans
throughout the study period and measuring the clinical cure rate, length of hospital stay, and
pertinent inflammatory biomarkers which snapshot the patient’s recovery such as white blood
cells, lymphocytes, C-reactive protein, and neutrophils.
From this experiment, the risk reduction (RR) for lung CT improvement among 749 the
experimental Chinese herbal medicine (CHM) and 653 controlled conventional Western
medicine (CWM) participants was 1.23, death in 256 CHM and 207 CWM showed a RR of 0.34
or indicating very little difference, and clinical symptoms (including sore throat, dry throat, chest
tightness, fever, and fatigue) were shown to be significantly improved through the use of scoring
the individual’s clinical symptoms. To gain a deeper understanding of the use of integrative
medicine, the risk reduction rate was compared between the CHM (experimental) and CWM
(controlled) groups that showed significant improvement in cough among 240 CHM and 182
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CWM participants of an RR value of 1.50, fever being significantly reduced within 433 patients
with a weight mean difference of -0.60, fatigue reduction among 167 patients in CHM and 140 in
CWM with a RR value of 1.73, TCM syndrome reduction within 141 CHM participants with a
weight mean difference of -6.60. In terms of the laboratory markers monitored throughout the
study, although there were no significant differences in the two groups in improving white blood
cell and lymphocyte count, in six trials the C-reactive protein showed a significant reduction in
the experimental group with a weight mean distribution of -8.91. Lastly, for participants to be
considered for discharge from the hospital, the clinical cure rate which includes four sub criteria
must be completed: significantly improved respiratory symptoms, completing two COVID-19
tests at least one day apart from each other which showed negative results, stabilizing and return
of body temperature within normal limits for at least three days, and results from the CT scan
which showed decreased inflammation of the pulmonary system. Of 1,523 participants, including
760 from the CHM and 763 from the CWM group, yielded a risk reduction rate of 1.18 in those
receiving the combination of traditional Chinese medicine alongside conventional Western
medical interventions.
The second article demonstrating adaptations made to TCM is titled, “Efficacy and safety
of Integrated Traditional Chinese and Western medicine for Coronavirus disease 2019 (COVID19): A systematic review and meta-analysis” (Liu et al., 2020). The purpose of the study was to
determine the efficacy and safety of using Traditional Chinese Medicine alongside Western
Medicine for COVID-19 patients also known as “integrative medicine”. For this study, 982
participants (ages 18 or older and clinically diagnosed with COVID-19) were included in the
control and experimental groups with studies ranging from 5 to 30 days with an average of 13.55
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days. Due to the ranging treatment time frames, this potentially hinders the results obtained as
the participants did not receive the treatment for an equal duration of time.
Four of the studies were randomized controlled trials and seven were case-control studies
which were assessed using the Cochrane Risk of Bias tool and Newcastle-Ottawa Scale
respectively. Patented Chinese medicine used for this trial includes Shufeng Jiedu Capsule,
Lianhua Qingwen granules, and QingFei TouXie FuZhengFang. The practices of Western
medicine incorporated in this study include respiratory assisted ventilation, antiviral agents such
as lopinavir and abidol, supportive care, and glucocorticoid therapy to inhibit inflammation.
Participants in the control group only received modern Western treatments for COVID-19
symptoms, while the experimental group received the integrated medicine practice of combining
TCM and Western medicine.
In terms of quantitative-wise, the risk ratio value (RR) was used for testing factors which
fell into the dichotomous data category of having two categories of outcomes, while the
weighted mean difference (WMD) was used for continuous testing factors such as the hospital
stay which could result in a large range of outcomes such as a couple of days to years.
Participants in the experimental group who received the integrated medicine treatment had an
overall better outcome than the control group for the following categories: response (RR=
1.230), severity of illness (RR=0.350), cure (RR=1.604), and hospital stay rate (WMD= -1.991).
About interpreting the risk ratio, the cure rate which resulted in a score of 1.604 means the odds
of the outcome in participants receiving the integrated medicine treatment are 1.604 times the
odds of the outcome happening in the controlled group (those who received a placebo) to be
cured of COVID-19. The use of integrated medicine for this particular group of patients showed
the ability to mitigate symptoms of cough, fatigue, anorexia, fever, fatigue time, chest tightness,
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and sputum production from the lungs or throat from coughing. Although clinical symptoms
which are deemed as subjective data were collected from the participants, other objective data
indicators were included such as measuring the C-reactive protein count, white blood cell,
lymphocyte percentage, and tumor necrosis factor-alpha. This study is the beginning of many
potential research topics regarding integrated medicine for diagnosed COVID-19 patients.
Overall, these two studies demonstrated the positive outcome of integrated medicine as
opposed to solely Western medicine in the treatment regimen for COVID-19 positive patients in
relieving the category of symptoms mentioned earlier such as fever and cough along with
improving the patient's laboratory indicators, specifically the lymphocyte percentage and
interferon-alpha levels back to within normal limit ranges.

Adaptations to Traditional Chinese Herbal Medicine for Use to Improve COVID-19 Patient
Outcomes
Two articles were chosen to demonstrate the adaptations to the use of traditional Chinese
herbal medicine which has been thoroughly studied to improve COVID-19 patient outcomes.
The adaptations made to Eastern medicine include providing the herbal and medicinal plants
native to China in a form of an injectable treatment while examining the potential treatment for
COVID-19 symptoms by providing a dual treatment of Chinese herbal medicine alongside
Western medicine.
In the article, “A real-world study on adverse drug reactions to Xuebijing Injection:
Hospital intensive monitoring based on 93 hospitals (31,913 cases)” the authors determined the
efficacy and safety of traditional Chinese medicine injections on patients located in China
diagnosed with community-acquired pneumonia, regardless of age and gender (Zheng et al.,
2019). Although their population of interest seems to be very broad, they narrowed down the
participants who would qualify to take part in this study by having either of the criteria listed.
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For example, to be declared as a “critically severe patient” they have to either have one of the
listed: respiratory failure requiring mechanical ventilation, shock, or organ failure needing
intensive care unit monitoring and treatment. Although this paper focuses on the effects of
COVID-19 on patients, it is important to note the significant correlation between those with
COVID-19 (experiencing mild to moderate respiratory symptoms) have a higher risk of
developing pneumonia and can even experience severe complications diagnosed as pneumonia.
With randomized controlled trials being conducted, 31,913 participants from 93 hospitals
(within August 2013 to August 2016) were divided into three groups: those who received no
treatment, a placebo, or were given an injection as the active treatment. The TCM injections used
in reducing community- acquired pneumonia symptoms include the Xiyanping, Xuebijing,
Reduning, Tanreqing, Xingnaojing, Shenfu, Shengmai, and Shenmai injection. From their study,
34 community-acquired pneumonia patients treated with the Chinese traditional injectable
medicine alongside receiving Western medicine before admission showed better recovery
outcomes. A major finding was that the Xuebijing injectable in particular enabled absorption of
pulmonary lesions and decreased the risk of patients with pneumonia from experiencing a septic
shock. Although the Xuebijing injectable yielded many positive results, there has not been any
research on whether it is effective on inflammation reduction and negative transformation of
nucleic acid as well as having a total of 96 adverse reaction cases to the Xuebijing injection
which equates to 0.3% of their total sample size.
Another article that focuses on determining the effectiveness of the Xuebijing injection
for diagnosed COVID-19 patients is named, “Effect of Xuebijing Injection on Inflammatory
Markers and Disease Outcome of Coronavirus Disease 2019” (Wen et al., 2020). Sixty clinically
diagnosed COVID-19 patients in severe conditions admitted to the Changsha Public Health
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Treatment Center in Changsha, China between January and March 2020 were divided into three
groups for this study. Before taking part in the study, the chosen participants had their blood
work taken to measure the pre- and post-treatment (taken eight days after the treatment course)
levels of C-reactive protein, acute physiology and chronic health evaluation II (APACHE II)
score, erythrocyte sedimentation rate, and COVID-19 test. The sixty participants were evenly
divided into three groups (each with twenty participants): the control group who received the
routine treatment for COVID-19, Xuebijing 50mL injection, and Xuebijing 100mL injection.
Across the three groups, after the treatment period was completed, a decrease in C-reactive
protein and erythrocyte sedimentation rate was observed, while the lymphocyte and white blood
cell count increased. Overall, participants receiving the Xuebijing 100mL injection had more
significantly improved results in the laboratory indicators mentioned above as well as their
APACHE II score which was lower than the control and Xuebijing 50mL participants.
Summarizing the Findings
Each of the studies included in this literature review has demonstrated positive and
promising results regarding the use of herbal and medicinal plants native to China and Thailand
to mitigate mild to moderate COVID-19 symptoms experienced in the qualified participants.
Beyond confirming the efficacy of Chinese and Thai herbal plants in diagnosed COVID-19
patients, a few studies have shown even better results when combining the practice with Western
medicine. The findings summarized can be used to further healthcare practices, although further
research would need to be conducted as many of the screening components used in the studies
published have been the first to be produced in the field to detect the safety and efficacy of the
Thai and Chinese herbal plants among COVID-19 patients. This creates a major limitation in the
results gained from the literature sources as many studies were unable to be replicated to obtain
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the same results due to time restraints and this matter being a recent topic of discussion in the
healthcare field. For further information regarding the articles used, please refer to Appendix A
for the summary of each literature review.

18

Proposal for Further Study
Although an immense amount of information was gained from the literature that was
reviewed, there are apparent gaps in the research. The use of herbal and medicinal plants for
mitigating COVID-19 symptoms is a fairly recent topic of discussion in the healthcare field.
However, the majority of research in the review focused on the patient in the hospital setting.
Therefore, a study is proposed to determine the efficacy of the native Chinese and Thai
medicinal plants for mitigating COVID-19 respiratory symptoms among residents of rural areas
of China and Thailand. The main research questions are:
● How do specific species of medicinal plants, native to China and Thailand, perform in
terms of mitigating mild respiratory symptoms, specific COVID-19, when used by
residents of China and Thailand who live in rural areas?
● How do the Chinese and Thai herbs compare to each other in regard to mitigating
patients' mild COVID-19 respiratory symptoms?
Theoretical Framework
The proposed study will expand based on the germ theory, a theory brought up by Robert
Koch which structured the research carried out by Louis Pasteur (A Theory of Germs, 2004).
The four Koch postulates describe the relationship of microscopic organisms as the cause of
disease in the host: (1) The microorganism must be found in diseased but not healthy individuals;
(2) The microorganism must be cultured from the diseased individual; (3) Inoculation of a
healthy individual with the cultured microorganism must recapitulate the disease; and (4) The
microorganism must be re-isolated from the inoculated, diseased individual and matched to the
original microorganism (Segre, 2013, pg. 2141-2142). In relation to COVID-19, the germ theory
provides an excellent foundation demonstrating how the SARS-CoV-2 virus is responsible for
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the COVID-19 disease. Additionally, the SARS-CoV-2 virus spreads through airborne particles
from an infected person’s respiratory droplets through the body of healthy and susceptible hosts
creating manifestations such as respiratory distress, fever, chills, sore throat, and new loss of
taste and/or smell.
This theory follows under the Western or biomedical system (as opposed to the
magicoreligious and naturalistic health systems) which describes the cause of disease as being a
result of abnormalities in the function of organs and body systems due to invasion of germs.
Interestingly, people in rural China and Thailand, may not identify the changes in health that
they experience with the SARS-CoV-2 virus as a communicable disease and not acknowledge
that there is a world-wide pandemic.
Primary Research Aims
The primary research aim for this proposed quasi experimental study (to be approved by
the Institutional Review Board [IRB]) is to determine the efficacy rates of native Thai and
Chinese medicinal plants in mitigating respiratory-specific COVID-19 symptoms. Other aims of
this study are to identify the benefits of herbal and medicinal plants as a practice in treating
COVID-19 positive patients residing in rural Thailand and China areas where medical resources
are limited and isolated.
Ethical Considerations
Interested participants will be informed by an IRB approved designee regarding the
study’s purpose, risks, benefits, research approach, and alternatives to participation concerning
the use of medicinal plants as a form of treatment for mild COVID-19 respiratory symptoms.
Potential participants will then be provided sufficient time to ask the researchers questions
related to the study and consider involvement prior to signing an informed consent which can be
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removed at any time of the study and will not hinder them in any way. As this study engages
with a vulnerable population group, participants will be informed of the risk and benefits and
protective measures will be taken to ensure the adverse risk is low through implementing
interventions which strictly follow the research design approved by the IRB to minimize
unnecessarily exposing participants to risk, while promoting beneficence, nonmaleficence, and
the participant’s autonomy throughout the study.
To establish the confidentiality of our participants, study identifiers will be used
throughout the preparation and duration of the experiment. A master document of the
participant’s name and their respective study identifiers will be secured on a password-protected
computer. To ensure the security of the documents used for this study, all files will be locked
with a password and documents will be encrypted when embedded into emails. Additionally,
only researchers in direct contact and working with the study participants will be discussing the
inputs, outputs, outcome, and goal for this study, while also ensuring that researcher bias is
minimized by strictly following the research plan and implementing parameters to reduce bias
(such as the triangulation method to increase validity and credibility of the research findings).
Research Method
Research Design
The design of this proposed research study will be carried out in a mixed manner, having
components of qualitative and quantitative study.

Research Population and Sample Size
A total of 1,500 participants will be recruited throughout rural China (750 residents) and
Thailand (750 residents) to be included in the study. The criteria to be used are as follows:
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between the ages of 18 and 65 years old, clinically diagnosed with COVID-19, and residing in a
geographically determined rural area in either Thailand or China, without any limitations on
nationality and gender.

Strategy for Recruitment
As this study is aimed to work with residents in rural areas of China and Thailand, they
tend to have limited resources and are isolated from hospitals and local clinics. The strategies
used for the recruitment of participants will be through snowball sampling. The researchers will
form a healthcare team and partner with a mobile clinic that travels throughout the countryside
and local public health nurses to inform the residents they are supporting when visiting their
homes for health check-ups or providing COVID-19 testing.

Statistical Analysis for Quantitative Research
A randomized controlled trial will be used to categorize the qualified participants into
one of three groups (each consisting of 500 participants): a controlled group of participants
receiving the placebo treatment, an experimental group receiving a Thai medicinal herb, and
another experimental group receiving a Chinese medicinal herb to test the efficacy of the
specified herbal plants as a form of treatment in mitigating respiratory specific COVID-19
symptoms among residents in rural areas of China and Thailand.
A mobile clinic with a healthcare team will be used in each country to visit the rural
communities targeted for participation. The mobile health clinic trailer will contain x-ray and CT
imaging equipment. The primary pre- and post-experimental indicators used to determine and
compare treatments in this study include a chest x-ray and/or lung CT scan to determine initial
lung damage, real-time polymerase chain reaction (PCR) diagnostic panel, a complete blood
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count panel, and other laboratory values such as white blood cell count, erythrocyte
sedimentation rate, prothrombin time. With data collected from the three groups, an analysis of
variance (ANOVA) will be used to compare the statistics obtained. Each arm of the study
(Control, Chinese Herb, and Thai Herb) is expected to run from seven to 30 days and participants
will be completing a daily survey ranking the intensity of their dyspnea, pain, and tiredness on a
numerical rating scale of 0 to 10 (ordinal data) to be analyzed using ANOVA.

Content Analysis for Qualitative Research
Pre- and post-study semi-structured interviews through focus groups (5-8 participants)
will be conducted by researchers working directly with this experiment to document the
participant’s own experiences, biases, and concerns. Before the interviews, participants will be
asked for consent to use information obtained and transcribed into a transcript to be included as
study data. Examples of the questions to be included in the interview are as follows:
1. Where is the closest clinic or hospital located? How many minutes away is the site?
2. What do you call this “health change” (i.e. the COVID-19 pandemic)?
3. How would members of your culture treat this condition (i.e. treat symptoms related to
the virus)?
4. What symptoms are you feeling and how long have you been experiencing them?
5. How has your experience with the use of herbal and medicinal plants compared to your
usual practices?
In terms of the content analysis for qualitative research, the researchers will search for similar
words and phrases throughout all of the focus groups to be organized into categories and
subunits to identify common themes (Fain, 2021, pg. 212).
Conclusion
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The use of native herbal and medicinal plants from China and Thailand as a means of
treating community-acquired pneumonia and mitigating mild-to-moderate COVID-19 symptoms
are shown to be a safe practice that yields successful results. The seven literature sources provide
a foundation for further research that could be the basis of evidence-based practice interventions
implemented in medical settings. The proposed research will advance the profession of nursing
by understanding the substantial significance of nonpharmacological interventions using herbal
and medicinal plants. Implementing this practice in rural areas eliminates the challenges of being
isolated and having inaccessible medical resources, while potentially reducing the morbidity and
mortality rate of these residents (especially those unvaccinated) which would otherwise lead to
rapid health deterioration.
Beyond the knowledge acquired, important next steps in this process would be to
determine the safety and efficacy rates of native Thai herbal plants used alongside Western
medicine in mitigating COVID-19 symptoms, use of this practice among vulnerable populations
such as children, geriatrics population, and pregnant women, and how these medicinal plants will
be distributed to those who need them.
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